Covid-19 Clinical Trial
Official title:
Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome
Multicentric case-control study that is aims at:
- evaluating the prevalence of pulmonary embolism among a large population of consecutive
patients admitted for COVID-19 pneumonia into two large university hospitals in Paris,
France: Groupe Hospitalier Paris Saint-Joseph (GHPSJ) and Hôpital Européen Georges
Pompidou (HEGP)
- and identifying the characteristics associated with pulmonary embolism by using a nested
case control study design within the patients who underwent either unenhanced computed
tomograpghy (CT) or CT pulmonary angiogram (CTPA) evaluation.
In December 2019, China reported the first cluster of severe acute respiratory syndrome due
to a new coronavirus (SARS-CoV-2). The disease rapidly spread into a global pandemic of
public health emergency worldwide leading to more than 330.000 deaths (data from May 25th,
2020). We have, to date, no demonstration on the efficacy of any drug to cure or prevent
severe evolution of the disease (COVID-19). The primary target of SARS-CoV-2 is the lung with
frequent occurrence of acute respiratory distress syndrome (ARDS) justifying supportive care,
including invasive mechanical ventilation (IMV). The characteristics of ARDS in COVID-19
patients appeared atypical due to the dissociation between initial well-conserved lung
compliance and severe hypoxemia, attributed to pulmonary vasoregulation disruption and local
thrombogenesis. Strikingly high D-dimers levels, caused by both inflammation storm and
coagulation activation, have been early reported in COVID-19 patients and have been
associated with increased mortality. A single observational study suggests that
anticoagulation is associated with a decreased mortality in severe COVID-19 patients. These
reports have led to several therapeutic propositions in terms of anticoagulant therapy from
worldwide scientific societies (Khider et al JMV 2020). Publications recently reported
thrombotic complications in series of severe COVID-19 patients admitted in ICU, but the
frequency of pulmonary embolism (PE) in larger cohort of COVID-19 patients of any severity
remains uncertain.
This cohort enrolled patients in whom PE is proven by CTPA and compared them into two
subgroups of controls matched for age and sex in whom PE was either excluded or non
suspected:
1. COVID-19 patients with a negative CTPA and
2. COVID-19 patients in whom only an unhenced CT was performed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|